Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab

被引：1

作者：

Naqvi, Syed ^{[1
]}

Shrestha, Asis ^{[1
]}

Alzubi, Marah ^{[2
]}

Alrawabdeh, Jawad ^{[2
]}

Thanendrarajan, Sharmilan ^{[1
]}

Zangari, Maurizio ^{[1
]}

van Rhee, Frits ^{[1
]}

Schinke, Carolina ^{[1
]}

Al Hadidi, Samer ^{[1
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR USA

[2] Univ Jordan, Dept Internal Med, Amman, Jordan

来源：

EJHAEM | 2024年 / 5卷 / 04期

关键词：

dysgeusia; multiple myeloma; talquetamab; weight loss;

D O I：

10.1002/jha2.971

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Talquetamab is an approved therapy for relapsed/referactory multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post-treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight during talquetemab treatment, with weight loss persisting in about half of the patients post-discontinuation. Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials complications and discomfort.

引用

页码：789 / 792

页数：4

共 50 条

[41] CARDIAC STRUCTURE AND FUNCTION IN PATIENTS TREATED WITH PROTEASOME INHIBITORS FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Dahm, Cherie
Mallugari, Ravinder
Ky, Bonnie
Cornell, Robert
Lenihan, Daniel
Gupta, Deepak K.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1085 - 1085
[42] Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).
Jakubowiak, Andrzej
Wang, Luhua
Orlowski, Robert Z.
Jagannath, Sundar
Siegel, David
Stewart, A. Keith
Kukreti, Vishal
Lonial, Sagar
McDonagh, Kevin T.
Vallone, Marcy
Kauffman, Michael
Vij, Ravi
BLOOD, 2009, 114 (22) : 725 - 726
[43] Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
Zhao, Fang
Yang, Bo
Wang, Juan
Zhang, Rui
Liu, Jing
Yin, Fenglei
Xu, Weixing
He, Chunyuan
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1525 - 1531
[44] LENALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Okada, K.
Okamoto, Y.
Tsukamoto, T.
Sugiura, H.
Matsui, H.
Ueda, T.
Jo, T.
Onishi, T.
Kunitomi, A.
Ueda, Y.
ANNALS OF ONCOLOGY, 2013, 24
[45] VDE for Relapsed/Refractory Multiple Myeloma in Elderly Patients
Mele, G.
Pinna, S.
Melpignano, A.
Quarta, G.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S12 - S12
[46] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
Stewart, A. Keith
FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
[47] Gemcitabine in Treating Patients with Refractory or Relapsed Multiple Myeloma
Zheng, Hua
Yang, Fan
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (21) : 9291 - 9293
[48] Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
Li, Chunrui
Zhou, Keshu
Hu, Yongxian
Zou, Dehui
Chen, Lijuan
Chen, Bing
Liu, Jing
Zhang, Xi
Ren, Hanyun
Hu, Kai
Liu, Peng
Mi, Jian-Qing
Li, Zhenyu
Ding, Kaiyang
Wang, Di
Wang, Wen
Cai, Songbai
Li, Jianyong
Song, Yongping
Huang, He
Qiu, Lugui
JAMA ONCOLOGY, 2024, 10 (12) : 1681 - 1688
[49] Teclistamab for relapsed refractory multiple myeloma patients on dialysis
Lebreton, P.
Lachenal, F.
Bouillie, S.
Pica, G. M.
Aftisse, H.
Pascal, L.
Montes, L.
Macro, M.
Johnson, N.
Harel, S.
Fernandez, M.
De Renzis, B.
Lioure, B.
Lazareth, A.
Javelot, M.
Louni, C.
Huart, A.
Perrot, A.
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 2077 - 2079
[50] TREATMENT RESPONSE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
Ioana, I.
Liviu, C.
Maria, C.
Claudiu, I.
Maria, I.
Mihai, I.
Dacian, O.
Ovidiu, P.
Cristina, S.
Despina, C.
Hortensia, I.
HAEMATOLOGICA, 2013, 98 : 614 - 614

← 1 2 3 4 5 →